Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Schumacher

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Molecular Modeling|November 1, 2005
Umpolung catalysts: comparative assessments on reactivitiesBernd Goldfuss, Maria Schumacher
The Journal of Biological Chemistry|March 24, 2005
The crystal structure of the collagen-like polypeptide (glycyl-4(R)-hydroxyprolyl-4(R)-hydroxyprolyl)9 at 1.55 A resolution shows up-puckering of the proline ring in the Xaa positionMaria Schumacher, Kazunori Mizuno, Hans Peter Bächinger
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 29, 2017
[Improving the visibility of rare diseases in health care systems by specific routine coding]Magdalena María Marx, Franzisca Marie Dulas, Katja Maria Schumacher
Plos One|April 5, 2013
IL-17A and IFN-γ synergistically induce RNase 7 expression via STAT3 in primary keratinocytesMaren Simanski, Franziska Rademacher, Lena Schröder, et al.
Research Square|May 25, 2026
DNA Mechanical Strain Steers Transcription Factor RecognitionAriel Afek, Minyi Yao, Michael O'Hagan, et al.
The Lancet. Oncology|December 21, 2010
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 studyUlrich Gatzemeier, Joachim von Pawel, Ihor Vynnychenko, et al.
The Oncologist|May 30, 2024
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusionLily C Pham, Lauryn Weller, Claudia N Gann, et al.
Iscience|December 11, 2020
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET AlterationsLinda Pudelko, Frank Jaehrling, Christof Reusch, et al.
Japanese Journal of Clinical Oncology|May 26, 2021
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION studyHiroshi Sakai, Masahiro Morise, Terufumi Kato, et al.
The Lancet. Oncology|November 8, 2011
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker, Jose R Pereira, Joachim von Pawel, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Molecular Modeling|November 1, 2005
Umpolung catalysts: comparative assessments on reactivitiesBernd Goldfuss, Maria Schumacher
The Journal of Biological Chemistry|March 24, 2005
The crystal structure of the collagen-like polypeptide (glycyl-4(R)-hydroxyprolyl-4(R)-hydroxyprolyl)9 at 1.55 A resolution shows up-puckering of the proline ring in the Xaa positionMaria Schumacher, Kazunori Mizuno, Hans Peter Bächinger
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 29, 2017
[Improving the visibility of rare diseases in health care systems by specific routine coding]Magdalena María Marx, Franzisca Marie Dulas, Katja Maria Schumacher
Plos One|April 5, 2013
IL-17A and IFN-γ synergistically induce RNase 7 expression via STAT3 in primary keratinocytesMaren Simanski, Franziska Rademacher, Lena Schröder, et al.
Research Square|May 25, 2026
DNA Mechanical Strain Steers Transcription Factor RecognitionAriel Afek, Minyi Yao, Michael O'Hagan, et al.
The Lancet. Oncology|December 21, 2010
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 studyUlrich Gatzemeier, Joachim von Pawel, Ihor Vynnychenko, et al.
The Oncologist|May 30, 2024
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusionLily C Pham, Lauryn Weller, Claudia N Gann, et al.
Iscience|December 11, 2020
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET AlterationsLinda Pudelko, Frank Jaehrling, Christof Reusch, et al.
Japanese Journal of Clinical Oncology|May 26, 2021
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION studyHiroshi Sakai, Masahiro Morise, Terufumi Kato, et al.
The Lancet. Oncology|November 8, 2011
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker, Jose R Pereira, Joachim von Pawel, et al.
Pageof 2